Management of pyoderma gangrenosum.
Management of pyoderma gangrenosum continues to be a therapeutic challenge, both because the low incidence of the disease makes it difficult to conduct large-scale randomized studies and because pathogenic mechanisms are not yet well defined. The selection of drugs and dosing schedules is therefore mainly guided by clinical experience.
Mokni
M
M
Department of Dermatology, La Rabta Hospital, Tunis, Tunisia.
Phillips
T J
TJ
D004205:Cromolyn Sodium / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014221:Triamcinolone / Q000627:therapeutic use*
D005938:Glucocorticoids; D007917:Leprostatic Agents; D014221:Triamcinolone; D004205:Cromolyn Sodium